Care Network Targets Vaporox’s VHT device integrates with existing wound care protocols and uses a no upfront investment model, making skilled nursing facilities, clinics, and wound care centers strong target customers. Propose pilot programs and co marketing with distributors to prove value quickly. The MiMedx collaboration provides a validation anchor for partners.

ROI Advantage FDA cleared technology paired with standard wound care delivers high healing outcomes, with an 84% success rate and 50-70% wound bed granulation in 4-6 weeks. Turn these results into ROI focused materials and calculators for procurement teams, emphasizing cost reductions and shorter treatment cycles.

Strategic Partnerships Strategic alliances with large wound care and medical device players can accelerate market reach; the MiMedx deal demonstrates a viable channel. Explore reseller agreements or bundled solutions to reach broader networks, including post acute care systems.

Expansion Opportunities Geographic and channel expansion opportunities exist across US post acute networks, clinics, and wound centers. Leverage Denver presence, FDA clearance, and reimbursement readiness to secure multi facility contracts and scale through partner ecosystems.

Operational Efficiency Operational efficiency and patient outcomes support payer friendly value propositions; highlight ease of integration, training, ongoing support, and potential reductions in labor costs and care duration to drive adoption among administrators and clinicians.